Archived Newsletters

51. 05.05.26 -- FDA Letters Made Public Are Creating New Risks 5/5/2026
    05/05/26 Outsourced Pharma Newsletter
52. 05.04.26 -- STREAM Edition: The Reality Of AI In Clinical Supplies 5/4/2026

    05/04/26 Outsourced Pharma Newsletter

53. 05.04.26 -- Kodak Flips The Script To Biopharma Manufacturing In Rochester 5/4/2026
    05/04/26 Outsourced Pharma Newsletter
54. 05.01.26 -- New Podcast Episodes: Reprogramming T Cells, Radiotherapeutics, Rewriting Disease Biology 5/1/2026
    05/01/26 Outsourced Pharma Newsletter
55. 05.01.26 -- The Quiet Case For Trusting CDMO Pricing 5/1/2026
    05/01/26 Outsourced Pharma Newsletter
56. 04.30.26 -- End-To-End ADC Manufacturing Works Best With Active Sponsor Oversight 4/30/2026
    04/30/26 Outsourced Pharma Newsletter
57. 04.29.26 -- The Top Drug Development Partners Talk A Good Game 4/29/2026
    04/29/26
58. 04.29.26 -- Navigating an Evolving Pharma Landscape with Strong CDMO Partnerships 4/29/2026

    04/29/26 Outsourced Pharma Newsletter

59. 04.28.26 -- What FDA CRLs Reveal, USP <665> Countdown, Biowaiver Webinar 4/28/2026

    04/28/26 Outsourced Pharma Newsletter

60. 04.28.26 -- End-To-End ADC Manufacturing Works Best With Active Sponsor Oversight 4/28/2026
    04/28/26 Outsourced Pharma Newsletter